CliffBio
small molecule

ACETYLCYSTEINE

ACETYLCYSTEINE

Loss of exclusivity—loss of exclusivity
CompanyExela Pharma Sciences Llc →See this company's full patent-cliff portfolio

Drug detail

Brand nameACETYLCYSTEINE
Active ingredientACETYLCYSTEINE
Strength20%
Dosage formSOLUTION
RouteINHALATION, ORAL
ModalitySmall molecule
FDA approvalNovember 2023
Marketing statusDISCN

More from Exela Pharma Sciences Llc

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ACETYLCYSTEINE patent cliff — loss of exclusivity — | CliffBio